STOCK TITAN

MARPAI REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Marpai, Inc. reported its first-quarter 2024 financial results, showcasing a reduction in operating expenses by over $5 million and net loss by over 50% compared to 2023. The company also highlighted a decrease in net revenues and gross profit, but a significant improvement in operating expenses and net loss. Marpai remains dedicated to reducing client costs and improving member care through operational and financial enhancements.

Positive
  • Marpai reduced operating expenses by over $5 million and saw a 52% improvement in operating loss compared to the same period in 2023.

  • The company is focused on enhancing operational efficiency, which has led to a significant reduction in expenses and the implementation of cost-saving programs.

  • Marpai added a new client and expanded its sales team with experienced industry executives, indicating a commitment to growth and client service.

Negative
  • Net revenues and gross profit saw a decline year over year, with net revenues down by 24% and gross profit down by 23%.

  • The company reported a net loss of $4.3 million for the first quarter of 2024, showcasing a 51% improvement compared to the same period in 2023.

  • Basic and diluted earnings per share were ($0.46) for the first quarter of 2024, an improvement from $1.22 per share in the first quarter of 2023.

Marpai, Inc.'s financial results indicate a significant reduction in both operating expenses and net loss, which may appeal to investors focused on cost control and improving financial health. However, the reported decrease in net revenues raises concerns about the company's top-line growth and market position. Notably, the 'off cycle' client addition and sales team expansion are strategic moves that could stabilize and potentially enhance revenue streams in future quarters.

The TPA market is known for its competitive landscape and Marpai's initiatives to adapt to market evolution through operational efficiency could resonate well with stakeholders. However, the client turnover mentioned may indicate volatility in customer loyalty. Investor sentiments may be influenced by the company's ability to translate its cost-saving measures into sustained revenue growth and market share expansion.

Reduces Operating Expense by over $5 million and Net Loss by over 50% compared to 2023

TAMPA, Fla., May 9, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI), an independent national Third-Party Administration (TPA) company transforming the $22 billion TPA market supporting self-funded employer health plans with affordable, intelligent, healthcare, today announced financial results for the first quarter of 2024. The Company expects to hold a webcast to discuss the results on May 10, 2024.

Q1 2024 Financial Highlights:

  • Net revenues were approximately $7.4 million for the three months ended March 31, 2024, down $2.3 million, or 24% lower year over year, compared to the three months ended March 31, 2023.
  • Gross profit was $2.5 million for the three months ended March 31, 2024, down $0.7 million, or 23% lower year over year compared to the three months ended March 31, 2023.
  • Operating expenses were $6.6 million for the three months ended March 31, 2024, an improvement of $5.2 million, or 44% lower year over year compared to the three months ended March 31, 2023.
  • Operating loss was $4.1 million for the three months ended March 31, 2024, an improvement of $4.5 million, or 52% lower year over year compared to the three months ended March 31, 2023.
  • Net loss was $4.3 million for the three months ended March 31, 2024, an improvement of $4.5 million, or 51% lower year over year compared to the three months ended March 31, 2023.
  • Basic and diluted earnings per share were ($0.46) for the three months ended March 31, 2024, an improvement of $1.22 per share year over year compared to the three months ended March 31, 2023.

"The market is evolving, and we're adapting our approach to better serve our clients' needs. While we saw some client turnover in the first quarter, we are confident that our new initiatives will lead to long-term revenue growth and profitability," said Damien Lamendola, Chief Executive Officer of Marpai. "We are very pleased to have added a new "off cycle" client in Q1 and the expansion of our sales team with two highly successful industry executives."

John Powers, Marpai President commented, "Marpai is delivering on its promise to save! Our focus on operational efficiency has significantly reduced operating expenses. Building on this success, as previously announced, we implemented an additional cost-reduction program expected to generate $3 million in annual savings. Marpai remains dedicated to its core mission: reducing client costs and improving member care through continuous operational and financial improvements."

Webcast and Conference Call Information

Marpai expects to host a conference call and webcast on Friday, May 10, 2024, at 8:30 a.m. ET to answer questions about the Company's operational and financial highlights for its first quarter ended March 31, 2024.

Investors interested in listening to the conference call may do so by dialing (800)-836-8184 for domestic callers or +1-646-357-8785 for international callers, or via webcast: https://app.webinar.net/MVqDW74kNpl

About Marpai, Inc.

Marpai, Inc. (Nasdaq: MRAI) is a leading, national TPA company bringing value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA sector serving self-funded employer health plans representing over $1 trillion in annual claims. Through its Marpai Saves initiative, the Company works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release. Investors are invited to visit https://www.ir.marpaihealth.com.

Forward-Looking Statement Disclaimer

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance," "may," "can," "could", "will", "potential", "should," "goal" and variations of these words or similar expressions. For example, the Company is using forward looking statements when it discusses that it is confident that its new initiatives will lead to long-term revenue growth and profitability and that its additional cost-reduction program is expected to generate $3 million in annual savings. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai's current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise.

More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai's filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.

MARPAI, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEET

(in thousands, except share and per share data)

(Unaudited)




March 31, 2024


December 31, 2023






ASSETS:





Current assets:





Cash and cash equivalents


$                851


$                    1,147

Restricted cash


12,761


12,345

Accounts receivable, net of allowance for credit losses of $25 and $25


366


1,124

Unbilled receivable


727


768

Due from buyer for sale of business unit


800


800

Prepaid expenses and other current assets


1,000


901

Total current assets


16,505


17,085






Property and equipment, net


579


611

Capitalized software, net


1,512


2,127

Operating lease right-of-use assets


2,311


2,373

Goodwill


3,018


3,018

Intangible assets, net


4,874


5,177

Security deposits 


1,267


1,267

Other long-term asset


22


22

Total assets


$           30,088


$                  31,680

LIABILITIES AND STOCKHOLDERS'  (DEFICIT) EQUITY





Current liabilities:





Accounts payable


$             3,824


$                    4,649

Accrued expenses


3,076


2,816

Accrued fiduciary obligations


9,510


11,573

Deferred revenue


1,481


661

Current portion of operating lease liabilities


523


512

Other short-term liabilities


1,709


632

Total current liabilities


20,123


20,843






Other long-term liabilities


19,724


19,401

Operating lease liabilities, net of current portion


3,547


3,684

Deferred tax liabilities


1,190


1,190

Total liabilities


44,584


45,118

COMMITMENTS AND CONTINGENCIES





STOCKHOLDERS' (DEFICIT) EQUITY





Common stock, $0.0001 par value, 227,791,050 shares authorized; 10,308,038 shares
   and 7,960,938 shares issued and outstanding at March 31, 2024 and
   December 31, 2023, respectively (1)


1


1

Additional paid-in capital


66,595


63,307

Accumulated deficit


(81,092)


(76,746)

Total stockholders' (deficit) equity


(14,496)


(13,438)

Total liabilities and stockholders' (deficit) equity


$           30,088


$                  31,680


(1) Reflects 1-for-4 reverse stock split that became effective June 29, 2023. See Note 1 to the unaudited condensed consolidated financial statements.

 

MARPAI, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(in thousands, except share and per share data)

(Unaudited)




Three Months Ended 



March 31, 2024


March 31, 2023

Revenue


$             7,385


$                    9,672

Costs and expenses





Cost of revenue (exclusive of depreciation and amortization
   shown separately below)


4,871


6,409

General and administrative


3,421


5,226

Sales and marketing


602


2,179

Information technology


1,124


2,187

Research and development


7


500

Depreciation and amortization


951


1,044

Facilities


474


650

Total costs and expenses


11,450


18,195

Operating loss


(4,065)


(8,523)

Other income (expenses)





Other income


120


50

Interest expense, net


(398)


(385)

Foreign exchange (loss) gain


(3)


(15)

Loss before provision for income taxes


(4,346)


(8,873)

Income tax expense



Net loss


$            (4,346)


$                  (8,873)

Net loss per share, basic & fully diluted (1)


$              (0.46)


$                    (1.68)

Weighted average common shares outstanding, basic and
   diluted (1)


9,405,775


5,290,661


(1) Reflects 1-for-4 reverse stock split that became effective June 29, 2023. See Note 1 to the unaudited condensed consolidated financial statements.

 

MARPAI, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands, except share and per share data)

(Unaudited)




Three Months Ended



March 31, 2024


March 31, 2023

Cash flows from operating activities:





Net loss


$            (4,346)


$                  (8,873)

Adjustments to reconcile net loss to net cash used in operating activities:





Depreciation and amortization


951


1,044

Share-based compensation


561


623

Common stock issued to vendors in exchange for services



79

Amortization of right-of-use asset


62


252

Non-cash interest


423


388

Changes in operating assets and liabilities:





Accounts receivable and unbilled receivable


800


(239)

Prepaid expense and other assets


(99)


162

Accounts payable


(825)


653

Accrued expenses


215


(1,416)

Accrued fiduciary obligations


(2,063)


Operating lease liabilities


(126)


(363)

Other liabilities


862


1,149

Net cash used in operating activities


(3,585)


(6,541)

Cash flows from investing activities:





Disposal of property and equipment



3

Net cash provided by investing activities



3

Cash flows from financing activities:





Proceeds from sale of future cash receipts on accounts receivable


1,509


Payments to buyer of receivables


(57)


Payments to seller for acquisition


(474)


Proceeds from issuance of common stock in a public offering, net


2,727


Net cash provided by financing activities


3,705







Net increase (decrease) in cash, cash equivalents and restricted cash


120


(6,538)






Cash, cash equivalents and restricted cash at beginning of period


13,492


23,117

Cash, cash equivalents and restricted cash at end of period


$           13,612


$                  16,579






Reconciliation of cash, cash equivalents, and restricted cash reported in
   the condensed consolidated balance sheet





Cash and cash equivalents


$                851


$                    6,174

Restricted cash


12,761


10,405

Total cash, cash equivalents and restricted cash shown in the condensed
   consolidated statement of cash flows


$           13,612


$                  16,579

Supplemental disclosure of non-cash activity





Measurement period adjustment to Goodwill


$                  —


$                         36

 

(PRNewsfoto/Marpai)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/marpai-reports-first-quarter-2024-financial-results-302141613.html

SOURCE Marpai

FAQ

What were Marpai's net revenues for the first quarter of 2024?

Marpai reported net revenues of approximately $7.4 million for the three months ended March 31, 2024.

How much did Marpai reduce its operating expenses by in the first quarter of 2024?

Marpai reduced its operating expenses by $5.2 million for the three months ended March 31, 2024, compared to the same period in 2023.

What was Marpai's net loss for the first quarter of 2024?

Marpai reported a net loss of $4.3 million for the three months ended March 31, 2024.

When will Marpai hold a webcast to discuss its financial results for the first quarter of 2024?

Marpai will hold a webcast to discuss its financial results on May 10, 2024.

How can investors listen to Marpai's conference call on May 10, 2024?

Investors can listen to Marpai's conference call by dialing (800)-836-8184 for domestic callers or +1-646-357-8785 for international callers, or via webcast.

Marpai, Inc.

NASDAQ:MRAI

MRAI Rankings

MRAI Latest News

MRAI Stock Data

21.65M
4.24M
61.1%
2.3%
1.95%
Insurance Agencies and Brokerages
Finance and Insurance
Link
United States of America
TAMPA

About MRAI

marpai health is working at the intersection of healthcare and deep learning, the most advanced form of artificial intelligence. our mission is to predict and prevent costly events in healthcare for the benefit of patients, providers and payors.